Takanori Maejima

4PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 28, 2026
Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.

|Nov 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans

|Feb 12, 2022
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.

Michiko Yamato, Jun Hasegawa, Takanori Maejima

|Aug 20, 2021
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.

Daisuke Okajima, Satoru Yasuda, Takanori Maejima

Pageof 1

Frequent Collaborators

2 joint publications

Toshinori Agatsuma

2 joint publications

Tsuyoshi Karibe

2 joint publications

Daisuke Okajima

1 joint publications

Tadashi Toki